This post was written by Lois Wilson, RT(R), CT, MR, ARRT, director, corporate imaging, Parkview Health.
Pluvicto® (lutetium-177-PSMA-617) injections are a cutting-edge treatment option for patients battling metastatic prostate cancer. This innovative therapy offers a promising new hope for individuals with advanced prostate cancer that has spread to other parts of the body, particularly for those who have not responded to conventional treatments.
What is Pluvicto?
Pluvicto is a targeted radioligand therapy that uses a radioactive substance to directly deliver radiation to prostate cancer cells. This therapy is administered as an injection in the Nuclear Medicine Department once every six weeks.
How does it work?
By attaching to the prostate-specific membrane antigen (PSMA) found on cancer cells, Pluvicto allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This highly effective treatment can shrink tumors, alleviate symptoms and improve quality of life for patients with limited options.
Who is eligible?
Pluvicto can help slow metastatic cancer, but it is not a cure and is not for everyone. Candidates must meet the following criteria:
-
PSMA-positive cancer: The cancer cells must express prostate-specific membrane antigen (PSMA), which allows Pluvicto to target them effectively.
-
Metastatic castration-resistant prostate cancer (mCRPC): This means the cancer has spread to other parts of the body and continues to progress despite hormone therapy or surgical treatments to lower testosterone.
-
Completed prior treatments: Candidates must have undergone standard therapies, such as chemotherapy or androgen receptor-directed treatments, but have seen limited or no success with these options.
Are there any side effects?
Individuals who receive treatment with Pluvicto report experiencing few to no adverse side effects. The most common side effects include:
-
Tiredness
-
Dry mouth
-
Nausea
-
Low blood platelet count
-
Loss of appetite
-
Changes in bowel movements, constipation or diarrhea
-
Vomiting
-
Weight loss
-
Abdominal pain
Parkview's commitment
Parkview is dedicated to providing the latest advancements in cancer care, so we have participated in clinical trials leading up to FDA approval of this treatment option. With the addition of Pluvicto, we continue to push the boundaries in treating complex conditions. Our expert oncology team works closely with patients to ensure the best possible outcomes, offering personalized care and support throughout their treatment journey. Together, we can bring new hope to patients facing this challenging diagnosis.
Learn more
Parkview's Imaging Department, in collaboration with the oncologists at Parkview Packnett Family Cancer Institute, now offers Pluvicto injections as a safe and effective prostate cancer treatment. Click here to learn more about our imaging services.
